-
- Tani Hidenori
- Department of Cardiology, Keio University School of Medicine, Japan Department of Prevention Center, Keio University School of Medicine, Japan
-
- Ieda Masaki
- Department of Cardiology, Keio University School of Medicine, Japan
この論文をさがす
説明
<p>There are high expectations regarding heart regeneration for refractory heart failure (HF). Transplantation of human pluripotent stem cell (hPSC)-derived cardiomyocytes (CMs) is expected to replace CMs lost due to HF, and various studies have been conducted to apply this therapy clinically. Though issues such as arrhythmias and immune rejection remain, the mass production of purified hPSC-derived CMs, their efficient transplantation, and methods to improve their engraftment pushed up the transplantation of hPSC-derived CMs to the clinical stage. In contrast, a direct cardiac reprogramming method has been developed, where cardiac fibroblasts are directly converted into CM-like cells without undergoing PSCs by overexpressing reprogramming factors. Although many challenges still remain in the clinical application of direct cardiac reprogramming, this can be a novel treatment which overcomes issues of transplantation of hPSC-derived CMs. </p>
収録刊行物
-
- Internal Medicine
-
Internal Medicine advpub (0), 2024
一般社団法人 日本内科学会
